Xeris Pharmaceuticals | XERS - Operating Profit


Xeris Pharmaceuticals reported $7.92M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Celltrion KRW 12.9B 822.77M Mar/2026
Cspc Pharmaceutical CNY 206.26M 1.02B Dec/2025
Deva Holding AS TRY 964.87M 240.32M Sep/2023
Dianthus Therapeutics USD -46.53M 23.01M Mar/2026
Divis Laboratories Ltd INR 8.14B 420M Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Kangmei Pharma CNY -10.94M 15.75M Mar/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 400K Dec/2024
Medical Developments International AUD -36K 444K Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neuren Pharmaceuticals AUD 17.01M 11.56M Dec/2025
Organigram Holdings CAD -9.79M 10.33M Mar/2026
Ovoca Bio EUR -1.16M 4.48M Jun/2025
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pharma Mar EUR 622K 42.99M Mar/2026
Qiagen NV USD 121.88M 15.41M Dec/2025
Sartorius EUR 160.7M 9.5M Mar/2026
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Tilray USD -20.01M 9.34M Sep/2025
Zealand Pharma A/S -707.05M 245.73M Dec/2025
Zz Pientze Pharmaceu CNY 837.81M 336.48M Mar/2026